Julie Ryan Wolf

Julie Ryan Wolf

Auto-generated profile, based on publicly available information

Julie Ryan Wolf

Department of Dermatology University of Rochester Medical Center Rochester New York USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2007 in The Oncologist
Verified
Journal Article
Open access
PDF file
MHMaarten Hofman
Maarten Hofman
JRJulie L. Ryan
Julie L. Ryan
CFColmar D. Figueroa-Moseley
Colmar D. Figueroa-Moseley
PJPascal Jean-Pierre
Pascal Jean-Pierre
GMGary R. Morrow
Gary R. Morrow
Fatigue is one of the most common and debilitating symptoms experienced by patients with cancer. Cancer-related fatigue (CRF) is characterized by feelings of tiredness, weakness, and lack of energy, and is distinct from the “normal” drowsiness experienced by healthy individuals in that it is not relieved by rest or sleep. It occurs both as a consequence of the cancer itself and as a side effect of cancer treatment, although the precise underlying pathophysiology is largely unknown. CRF may be an early symptom of malignant disease and is reported by as many as 40% of patients at diagnosis. Virtually all patients expect fatigue from cancer therapy. Up to 90% of patients treated with radiation and up to 80% of those treated with chemotherapy experience fatigue. CRF continues for months and even years ollowing completion of treatment in approximately one third of the patients with cancer. The impact of CRF on a patient's quality of life (QoL), particularly in relation to physical functioning and the ability to perform activities of daily living, is both profound and pervasive. In addition, CRF is associated with considerable psychological distress and can impose a significant financial burden by limiting a patient's ability to work. These effects can extend to caregivers and family members, who may also have to reduce their working capacity in order to provide additional care for a patient with CRF. This paper examines the prevalence of CRF and explores the impact of this distressing symptom on patients' functioning and QoL. Disclosure of potential conflicts of interest is found at the end of this article.

1 May 2007 in The Oncologist
Verified
Journal Article
Open access
PDF file
JRJulie L. Ryan
Julie L. Ryan
JCJennifer K. Carroll
Jennifer K. Carroll
Elizabeth P RyanElizabeth P Ryan
Elizabeth P Ryan
KMKaren M. Mustian
Karen M. Mustian
KFKevin Fiscella
Kevin Fiscella
GMGary R. Morrow
Gary R. Morrow
Cancer-related fatigue (CRF) is one of the most prevalent symptoms patients with cancer experience, both during and after treatment. CRF is pervasive and affects patients' quality of life considerably. It is important, therefore, to understand the underlying pathophysiology of CRF in order to develop useful strategies for prevention and treatment. At present, the etiology of CRF is poorly understood and the relative contributions of the neoplastic disease, various forms of cancer therapy, and comorbid conditions (e.g., anemia, cachexia, sleep disorders, depression) remain unclear. In any individual, the etiology of CRF probably involves the dysregulation of several physiological and biochemical systems. Mechanisms proposed as underlying CRF include 5-HT neurotransmitter dysregulation, vagal afferent activation, alterations in muscle and ATP metabolism, hypothalamic–pituitary–adrenal axis dysfunction, circadian rhythm disruption, and cytokine dysregulation. Currently, these hypotheses are largely based on evidence from other conditions in which fatigue is a characteristic, in particular chronic fatigue syndrome and exercise-induced fatigue. The mechanisms that lead to fatigue in these conditions provide a theoretical basis for future research into the complex etiology of this distressing and debilitating symptom. An understanding of relevant mechanisms may offer potential routes for its prevention and treatment in patients with cancer.Disclosure of potential conflicts of interest is found at the end of this article.

1 March 2012 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
PDF file
JRJulie L. Ryan
Julie L. Ryan
Skin changes caused by ionizing radiation have been scientifically documented since 1902. Ionizing radiation is a widely accepted form of treatment for various types of cancer. Despite the technological advances, radiation skin injury remains a significant problem. This injury, often referred to as radiation dermatitis, occurs in about 95% of patients receiving radiation therapy for cancer, and ranges in severity from mild erythema to moist desquamation and ulceration. Ionizing radiation is not only a concern for cancer patients, but also a public health concern because of the potential for and reality of a nuclear and/or radiological event. Recently, the United States has increased efforts to develop medical countermeasures to protect against radiation toxicities from acts of bioterrorism, as well as cancer treatment. Management of radiation dermatitis would improve the therapeutic benefit of radiation therapy for cancer and potentially the mortality expected in any “dirty bomb” attack. Currently, there is no effective treatment to prevent or mitigate radiation skin injury. This review summarizes “the good, the bad, and the ugly” of current and evolving knowledge regarding mechanisms of and treatments for radiation skin injury.

1 July 2013 in Radiation Research
Verified
Journal Article
Closed access
PDF file
JRJulie L. Ryan
Julie L. Ryan
CHCharles E. Heckler
Charles E. Heckler
MLMarilyn Ling
Marilyn Ling
AKAlan Katz
Alan Katz
JWJacqueline P. Williams
Jacqueline P. Williams
GMGary R. Morrow
Gary R. Morrow
Radiation dermatitis occurs in approximately 95% of patients receiving radiotherapy (RT) for breast cancer. We conducted a randomized, double-blind, placebo-controlled clinical trial to assess the ability of curcumin to reduce radiation dermatitis severity in 30 breast cancer patients. Eligible patients were adult females with noninflammatory breast cancer or carcinoma in situ prescribed RT without concurrent chemotherapy. Randomized patients took 2.0 grams of curcumin or placebo orally three times per day (i.e., 6.0 grams daily) throughout their course of RT. Weekly assessments included Radiation Dermatitis Severity (RDS) score, presence of moist desquamation, redness measurement, McGill Pain Questionnaire-Short Form and Symptom Inventory questionnaire. The 30 evaluable patients were primarily white (90%) and had a mean age of 58.1 years. Standard pooled variances t test showed that curcumin reduced RDS at end of treatment compared to placebo (mean RDS = 2.6 vs. 3.4; P = 0.008). Fisher's exact test revealed that fewer curcumin-treated patients had moist desquamation (28.6% vs. 87.5%; P = 0.002). No significant differences were observed between arms for demographics, compliance, radiation skin dose, redness, pain or symptoms. In conclusion, oral curcumin, 6.0 g daily during radiotherapy, reduced the severity of radiation dermatitis in breast cancer patients.

5 August 2011 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
JRJulie L. Ryan
Julie L. Ryan
CHCharles E. Heckler
Charles E. Heckler
JRJoseph A. Roscoe
Joseph A. Roscoe
SDShaker R. Dakhil
Shaker R. Dakhil
JKJeffrey Kirshner
Jeffrey Kirshner
GMGary R. Morrow
Gary R. Morrow

13 March 2012 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
JRJulie L. Ryan
Julie L. Ryan
YSYou-Jun Shen
You-Jun Shen
DMDouglas R. Morgan
Douglas R. Morgan
LTLeigh B. Thorne
Leigh B. Thorne
SKShannon C. Kenney
Shannon C. Kenney
MGMargaret Gulley
Margaret Gulley